Related Experiment Video
Updated: Jun 22, 2026
23:56
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
Published on: October 31, 2010
Developing nations and the compulsory license: maximizing access to essential medicines while minimizing investment
1University of Connecticut School of Business, USA.
Summary
Developing countries can improve access to essential medicines using compulsory licensing. However, social and political factors are crucial for effective implementation and minimizing side effects.
Area of Science:
- Health Policy
- Intellectual Property Law
- International Public Health
Background:
- Compulsory licensing is a mechanism for improving access to essential medicines in developing nations.
- Existing legal frameworks for compulsory licensing require careful consideration of external factors.
- Public health goals can be hindered by inadequate attention to socio-political conditions.
Purpose of the Study:
- To analyze how developing countries can optimize access to essential medicines under compulsory licensing.
- To identify strategies for minimizing adverse side effects within this legal framework.
- To explore the influence of external socio-political conditions on the effectiveness of compulsory licensing.
Main Methods:
- Literature review of compulsory licensing cases and international health regulations.
- Analysis of legal frameworks governing intellectual property and essential medicines.
- Case study approach examining socio-political factors in developing countries.
Main Results:
- Compulsory licensing can enhance medicine accessibility but requires tailored legal and policy approaches.
- Minimizing side effects necessitates robust regulatory oversight and pharmacovigilance.
- External factors like political stability and social infrastructure significantly impact licensing effectiveness.
Conclusions:
- Effective compulsory licensing for essential medicines demands integration with broader public health strategies.
- Addressing socio-political determinants is paramount for successful implementation and equitable access.
- Policy recommendations should focus on strengthening national capacities and international cooperation.
Related Concept Videos
01:26Methods Of Healthcare Delivery System
At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is limited...
01:02Prescription, Nonprescription and Orphan Drugs
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:28International Nursing Organizations II
The World Health Organization (WHO) is a specialized agency of the United Nations based in Geneva. The WHO has many initiatives that center around health. Primarily, they lead global efforts to expand universal health coverage using science-based policies and programs. They are also responsible for shaping health research agendas and developing norms and standards.
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
The WHO provides expert team support, including funding, vaccines, testing, and treatment tools at the country level to fight...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).